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Zika virus (ZIKV) infection of pregnant women is associated with pathologic complications of
fetal development. Here, we infect pregnant rhesus macaques (Macaca mulatta) with a
minimally passaged ZIKV isolate from Rio de Janeiro, where a high rate of fetal development
complications was observed. The infection of pregnant macaques with this virus results in
maternal viremia, virus crossing into the amniotic fluid (AF), and in utero fetal deaths. We
also treated three additional ZIKV-infected pregnant macaques with a cocktail of ZIKV-
neutralizing human monoclonal antibodies (nmAbs) at peak viremia. While the nmAbs can
be effective in clearing the virus from the maternal sera of treated monkeys, it is not sufficient
to clear ZIKV from AF. Our report suggests that ZIKV from Brazil causes fetal demise in non-
human primates (NHPs) without additional mutations or confounding co-factors. Treatment
with a neutralizing anti-ZIKV nmAb cocktail is insufficient to fully stop vertical transmission.
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ZIKV has emerged in Brazil as a significant new threat tohuman health and has been linked to neurological com-plications including Guillain–Barré syndrome and fetal
developmental defects1–5. The birth defects defined as congenital
Zika syndrome (CZS) include, in addition to microcephaly, health
complications involving vision, hearing, seizures, and motor
disabilities1, 5. In Rio de Janeiro, 42% of fetuses of pregnant
women infected with ZIKV had abnormalities2. Varying inci-
dence of CZS have been reported2, 4, 6 with considerable con-
troversy surrounding whether ZIKV alone is sufficient to cause
fetal developmental problems7.
Non-human primate (NHP) species are considered the best
animal models of human pregnancy and placentation8. While
several groups have reported severe pathology of the ZIKV-
infected fetus, it has been difficult to demonstrate fetal demise in
infected pregnant macaques9–11. Fetal brain lesions were reported
in NHPs after infection of a third trimester pigtail macaque with a
high dose (5 × 107 pfu) of a Cambodian ZIKV isolate12. Recently,
Mohr et al.13 have reported fetal demise following ZIKV
PRVABC59 infection in a rhesus macaque. Nonetheless, this
animal also had a bacterial infection, and it remains unclear if
ZIKV infection alone is sufficient to cause demise of the rhesus
fetus.
Here we show that the ZIKV Rio U-1/2016 strain, isolated
from the urine of a pregnant woman living in a region with high
incidence of CZS, causes fetal demise in a NHP host. We have
infected 11 rhesus macaques with ZIKV, at different times during
the pregnancy. We inoculated the pregnant rhesus macaques with
10,000 plaque forming units (pfu) of a minimally passaged ZIKV
isolate from Rio de Janeiro, where a 42% rate of fetal develop-
mental problems was previously observed in pregnant women.
This virus caused lethality in AG129 mice, at lower doses than
other common ZIKV isolates. In infected pregnant macaques, it
resulted in prolongued maternal viremia and viral crossing into
the amniotic fluid (AF) of five pregnant macaques. Importantly,
two fetuses of three dams infected in the first trimester died in
utero. In one of these fetuses, ZIKV was present in the AF and
chorionic fluid (CF) (>105 copies ml−1) at the time of fetal
demise. We also treated three additional ZIKV-infected pregnant
animals with a cocktail of ZIKV-neutralizing human monoclonal
antibodies (nmAbs) at peak viremia. While the nmAbs were
effective in clearing the virus from the sera of two of the three
treated animals, ZIKV was still detected in the AF of one of the
treated animals. Our results indicate that ZIKV Rio U-1/2016 is
sufficient for causing fetal demise in the rhesus NHP model of
ZIKV-infection. Furthermore, treatment with a potent nmAb
cocktail did not prevent vertical transmission. Therapeutic
approaches for ZIKV using nmAbs will have to specifically
designed for reaching effective concentrations in the fetal
compartment.
Results
ZIKV Rio U-1/2016 infection of mice and rhesus macaques.
Infection of nonpregnant AG129 mice with the Rio U-1/2016
isolate14 showed that this virus was lethal after challenge (Sup-
plementary Fig. 1). Furthermore, low doses of this virus were
lethal to mice, indicating that this strain might be more patho-
genic than the other common ZIKV PRABC59 or Paraiba/2015
isolates (Supplementary Fig. 1). We then used this low-passaged
ZIKV isolate to challenge rhesus macaques in different phases of
pregnancy (Fig. 1; Supplementary Table 1). Pregnancy in the
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Fig. 1 Pregnant NHP study design. a We challenged 11 rhesus macaques with 10,000 pfu of ZIKV Rio U-1/2016 during the first (blue), second (red), and
third (black) trimester (55 days each) of pregnancy. Fetal outcomes; deceased/unresponsive, killed, or alive are indicated by black, gray, and white, circles,
respectively. b Dam and fetal samples were collected at the indicated time points
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equivalent in developmental landmarks to the trimesters of
human pregnancy15. Ultrasound-guided amniocentesis was per-
formed, and sera were collected at the indicated time points
(Figs. 1 and 2).
Fetal outcomes of ZIKV-infected pregnant macaques. The
pregnant macaques had viremia beyond day 7 post infection,
which contrasts to non-pregnant macaques in prior studies16, in
which viremia was cleared by day 7 (Fig. 2). The first animals to
be born after ZIKV infection (F08, F09, F10, and F11) were
delivered ~7 weeks post challenge of the third trimester animals.
One of these infants, F11, was not responsive after delivery and
was killed. We looked for the presence of viral nucleic acid by
qRT-PCR in F11’s necropsied tissues (placenta, umbilical cord,
and brain), but could not detect virus. Despite having the most
prolonged viremia of the third trimester infected animals, the AF
was negative for ZIKV RNA at the time of the C-section. The
other infants from dams infected during the third trimester had
no apparent deficiencies.


















































































































































































































































































































































Fig. 2 Pregnant macaques have extended viremia and transmit virus to the fetus. Blood and AF were collected at the indicated time points. At time of C-
section or fetal demise, CF was also harvested. Serum (filled square), AF (open square), CF (light blue square) viral loads for 11 macaques in the first (blue),
second (red), or third (black) trimester of pregnancy are shown. Date of C-section is indicated by an arrow
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Three of the four dams infected during the second trimester
experienced transfer of ZIKV to the AF. In two of these dams,
M04 and M05, viral levels in the AF were higher than
observed in the sera of the dams. Furthermore, M05 virus was
observed in the AF when viral RNA was not detected in the
maternal serum. In spite of the presence of viral RNA in the AF,
these pregnancies were carried to term with no apparent
complications.
Notably, two of the three dams challenged during the first
trimester of pregnancy experienced fetal demise. Twenty-one
days after inoculation of one of the first trimester macaques,
ultrasound examination revealed that the fetus from dam
M01 was no longer viable. The associated fetal fluids were
collected by C-section and were analyzed for the presence of
virus. ZIKV was present in both the CF (~660,000 viral RNA
copies ml−1) and AF (~500,000 viral RNA copies ml−1) at
a time when there was no virus detected in the serum of the dam
at 21 days post-infection (Fig. 2). Similarly, dam M03
experienced fetal loss 89 days after infection. Thus, two of the
three first trimester dams challenged with ZIKV experienced fetal
loss. Unfortunately, the tissues from the lost fetuses were
extensively autolyzed at time of collection, which limited our
ability to detect virus or evaluate the tissue pathology. We were
unable to detect virus in the tested fetal tissues (lymph nodes,
brain). Using a comparable study design, Mohr et al.13 have
recently reported ocular pathology, prolonged viral replication in
maternal and fetal macaque tissues, and fetal demise following
ZIKV PRVABC59 infection in a rhesus macaque. However, a
concomitant bacterial infection during that pregnancy obfuscated
the association of the adverse pregnancy outcomes with the ZIKV
challenge.
The highest risk of severe human CZS occurs following ZIKV
infection in the first trimester of pregnancy2, 4. Similarly, two of
the three pregnant macaques challenged with ZIKV in the first
trimester resulted in fetal demise. The observed fetal loss in the
first trimester of pregnancy is consistent with another report of
ZIKV-associated fetal demise in macaques13. Importantly, fetal
loss has been only rarely observed in studies involving dams in
the first trimester at the Tulane National Primate Research Center
(TNPRC). Even after cytomegalovirus challenge of first trimester
pregnant rhesus macaques in a prior study, no fetal loss was
observed in immunocompetent animals (n= 3), despite repeated
amniocentesis and detection of virus in the AF17. Likewise, the
fetuses from all five control animals of a malaria infection study
during pregnancy were brought to term without complications18.
Furthermore, no spontaneous miscarriages were observed in a
group of 30 pregnant rhesus monkeys that were monitored by
ultrasound19. The overall miscarriage rate has been
previously estimated to be 4–7% of known pregnancies in the
TNPRC rhesus breeding colony19. Of note, these aforementioned
studies had experimental designs similar to the current ZIKV
challenge, including procedures and collection schedules, using
macaques from the same colony. Thus, fetal death is a rare
outcome for healthy pregnant macaques at the TNPRC. Even
though our study is limited by the lack of a control group, the
absence of fetal demise in similar studies with repeated
amniocentesis suggests that ZIKV causes fetal demise in
macaques.
Treatment of ZIKV-infected pregnant macaques. We next
attempted to block fetal infections with a cocktail of ZIKV-
nmAbs. We recently demonstrated that this SMZAb cocktail
prevented ZIKV infection of non-pregnant adult rhesus maca-
ques16. As a strategy to treat ZIKV-infected pregnant mothers
and their fetuses, we delivered our cocktail (each nmAb delivered
at 20 mg kg−1) to three macaques during peak viremia (Fig. 3a) at
day 3 post-infection, at a time when pregnant women might first
notice symptoms of ZIKV. We engineered these nmAbs with Fc
LALA mutations20 that abrogate Fc-gamma receptor binding to
eliminate potential therapy-mediated antibody-dependent
enhancement. We monitored viral loads in the mother’s serum
and the AF. We challenged one additional pregnant animal as a
contemporaneous untreated control (M15). The SMZAb cocktail
attained a peak concentration of 600 µg ml−1 of sera and 12 µg ml
−1 of AF (Fig. 3b). The ZIKV-challenged animals had peak vir-
emias of 105–106 vRNA copies ml−1 of sera on day 3 post
infection (Fig. 3c). The administration of the nmAb cocktail
completely cleared viremia in the blood of two of three treated
animals by day 5 (Fig. 3c). Surprisingly, AF from one of these
animals (M13) was positive for ZIKV at day 16, post infection,
more than 9 days after viremia in the maternal blood was cleared.
Our mAb cocktail failed to control viremia in one of the treated
pregnant dams and virus crossed the placenta in one of the other
two treated macaques. Since these third trimester dams were close
to delivery, our protocol called for the termination of the
experiment at 14–21 days post treatment. Given that these treated
macaques were late stage third trimester dams, we would be
unlikely to see any fetal complications. Nevertheless, we
attempted to amplify ZIKV from all four fetuses but could not
amplify virus from any of the three treated fetuses. The fetus from
the control animal (M15) was infected, and we were indeed able
to detect ZIKV RNA in the AF (1.7 × 105 vRNA copies ml−1),
fetal lymph node (6.1 × 104 vRNA copies mg−1), and fetal serum
(2.4 × 103 vRNA copies ml−1). In conclusion, the experiment
shows clearly that a nmAb cocktail that protects adults from
infection16 did not abrogate viremia in one of three macaques.
Furthermore, in the two macaques in which viral replication was
curtailed, virus was seen in the AF at a time when there was no
detectable virus in the maternal circulation. Thus, mAb treatment
following ZIKV infection in pregnant subjects is unlikely to
prevent transfer of virus to treated fetuses.
Viral sequences. To determine if any intrahost ZIKV genetic
variants were associated with acute viremia, in utero transmis-
sion, or fetal demise, we sequenced the viral inoculum, virus in
the dams’ serum (n= 11), and virus from the AF (n= 4) and CF
(n= 1; Fig. 4; Supplementary Table 2). Consistent with other
studies21, 22 using non-pregnant macaques, we found that acute
viremia in pregnant macaques was not associated with significant
ZIKV genetic change (Fig. 4a,b). In fact, we only detected one
nonsynonymous intrahost variant at >25% frequency in serum
from 11 pregnant macaques (animal M06, C6472T 40% fre-
quency), and it was also present in the inoculum at a 2% minor
allele frequency (Supplementary Table 2). We only detected five
ZIKV variants of >25% frequency in the AF from four animals
(Fig. 4a,b), none of which were detected in the inoculum (Sup-
plementary Table 2). However, most of the variants were
synonymous (3/5) and none were convergent (i.e., found in more
than one animal). These data suggest that random genetic bot-
tlenecks, rather than selective barriers, were the strongest evolu-
tionary forces during in utero transmission. Moreover, no ZIKV
variants were associated with fetal demise in our cohort. Thus,
our ZIKV isolate (Rio U-1/20163) does not require any additional
mutations to infect pregnant primates, traverse the placenta, or
cause fetal disease. Due to our limited sampling, however, it is
possible that other ZIKV genetic factors could affect fetal infec-
tion or disease.
We also investigated if escape mutations could explain viremia
in the nmAb-treated animal M12 (Fig. 4c). Our sequencing data
from the serum of this viremic animal did not reveal any de novo
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escape mutations in the ZIKV envelope coding region. Thus,
replication of the viral swarm of the wild-type virus in maternal
blood and the AF can occur despite treatment of pregnant
animals with a potent ZIKV nmAb cocktail.
Discussion
We have shown that ZIKV infection causes fetal demise in an
experimental NHP model. We used a relatively low challenge
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Fig. 3 Therapeutic administration of the SMZAb cocktail to ZIKV-infected pregnant Indian-origin rhesus macaques blocks maternal viremia but does not
prevent transmission of virus to fetus. a Treatment study design. Four pregnant rhesus macaques were challenged with 10,000 PFU of ZIKV Rio U-1/2016.
On day 3 post challenge, we administered a cocktail containing the three nmAbs, SMZAbs 1, 2, and 5 at a dose of 20mg kg−1 each to three rhesus
macaques (Group 1). An untreated animal was used as a control (Group 2). Four macaques infected in the third semester of pregnancy (M8–M11) were
used as historical controls. b Serum and AF were collected at the indicated time points for viral load and IgG measurements. c Serum viral loads for
SMZAb-treated (open symbols) and control (solid square) macaques
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42% of ZIKV-infected pregnancies resulted in CZS2. Infection of
pregnant macaques with this stock caused extended viremia in
the pregnant dams, ZIKV transfer to the AF in almost half of the
pregnancies, and fetal demise of three fetuses. The CDC clinical
guidance for the management of pregnant ZIKV patients is to
perform PCR in maternal samples24. However, our observation of
ZIKV RNA in the AF during aviremic periods in the mother in
four animals suggests that ZIKV RNA testing in maternal blood
might not be a reliable indicator of fetal infection. No specific
ZIKV mutations were required for in utero transmission or fetal
demise. These results suggest that wild type circulating ZIKV can
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Fig. 4 De novo mutations in the consensus sequences are not required for in utero transmission, fetal demise, or antibody escape during pregnancy. ZIKV
from serum and AF was sequenced using a PCR amplicon-based approach. A very conservative 0.25 frequency cut-off was used detect high frequency
intrahost variants. a ZIKV intrahost variant frequencies were plotted by the sample source (serum or AF) and days post infection. All blue lines indicate
different ZIKV variants sequenced from the same macaque (M04). b ZIKV intrahost variants >0.25 corresponding to a specific macaque, trimester of
infection, and fetal demise are also shown in a table for clarity. c Following nmAb cocktail treatment, one pregnant NHP (M12) failed to control viral
replication in the blood. Intrahost ZIKV variants sequenced from the serum of M12 and a no-antibody control were plotted by frequency and days post
infection. Variants shown as solid lines represent nonsynonymous mutations and variants shown as dashed lines represent synonymous. The dotted lines
at 0.25 frequency represent the limits of detection (LOD)
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shown that passive administration of a nmAb reduced, but did
not prevent, ZIKV placental viremia in a fetal infection model of
pregnant mice25. Of note, in contrast to rodents, the placentation
of NHPs have marked developmental similarities to humans, in
terms of placenta type, extent of cell invasiveness, and cell layer
composition26. It remains unclear why the passive administration
of a nmAb cocktail failed to block ZIKV transmission to the NHP
fetal compartment. It is possible that the levels of nmAbs that
reached this site (~10% of maternal serum levels) were insuffi-
cient to prevent replication.
ZIKV infection during the first two trimesters of pregnancy holds
the highest risk of severe fetal disease for ZIKV-infected
mothers2, 4. Thus, effective therapies of any nature will have to
reach the fetus during this early period, in effective amounts and
without toxicity. While fetal immunity is acquired through pla-
cental translocation of maternal IgG26, most of the IgG transport
occurs in the last trimester of the pregnancy. It is unlikely, then, that
our nmAb cocktail would reach the fetal compartment at earlier
points in the pregnancy. However, it may be possible to enhance
the rate of transplacental mAb transport. Further modification of
our nmAbs with mutations that facilitate FcRn-mediated func-
tions27 may be necessary for the success of this approach.
Methods
Animal experiments. The 15 Indian origin rhesus macaques (Macaca mulatta)
utilized in this study were housed at the TNPRC. The TNPRC is fully accredited by
AAALAC International (Association for the Assessment and Accreditation of
Laboratory Animal Care), Animal Welfare Assurance No. A3180-01. Animals were
cared for in accordance with the NRC Guide for the Care and Use of Laboratory
Animals and the Animal Welfare Act Animal experiments were approved by the
Institutional Animal Care and Use Committee of Tulane University (protocol
P0336). Pregnant macaques were selected based on availability and were not
randomized during assignment. No blinding was done.
Male and female AG129 mice lacking interferon type I and type II receptors
were produced from an in-house colony. The original five breeding pairs of AG129
mice were obtained in 2008 from Dr. Robert Schreiber, Washington University
Medical School (Saint Louis, MO). Groups of five mice, from 5 to 9 weeks of age
and an average weight of 23.3 ± 3.4 g, were challenged s.c. in the inguinal fold with
various dilutions of ZIKV. Mice were observed twice-daily throughout the study for
signs of disease and mortality. Mice were humanely killed when neurological
manifestations of virus infection, including loss of motility, lateral recumbancy,
weight loss >30% or the inability of the mice to access food and water. The death
date for animals that met the humane killing criteria was recorded as the day after
they were killed. All work was done in the AAALAC-accredited Laboratory Animal
Research Center at Utah State University under institutionally approved protocols.
Fetal tissues were collected in necropsies performed after fetal demise (C-
sections). The materials sampled depended on the status of tissue preservation, but
included brain, optic nerves, lymph nodes, placenta, cord-blood, bone marrow,
spinal cord, spleen, liver, and kidney.
Viruses and challenge. ZIKV strain Rio U-1/2016 was isolated in Rio de Janeiro,
Brazil in 2016 (KU926309). Viral challenge stocks were prepared by propagating
the virus in Vero cells Vero (American Type Culture Collection CCL81TM) for
two passages post-virus isolation14. The stocks were quantitated by viral plaque
assay. The viral stocks were diluted in Leibovitz’s L-15 and SPG media as described
previously28. All animals were challenged via the subcutaneous route, with 10,000
PFU.
Passive antibody administration. A cocktail of three anti-ZIKV mAbs was pro-
duced by combining: SMZAb1, SMZAb2, and SMZAb516. Each mAb was delivered
at a dose of 20 mg kg−1. The macaques were separated in two groups, as follows:
Group 1 (SMZAb cocktail, n= 3); Group 2 (untreated, n= 1). The nmAb cocktail
was prepared in saline and administered intravenously into each animal. All ani-
mals were infused with the nmAb cocktail 3 days post challenge. After the chal-
lenge, we collected serum and AF at the indicated time points to measure viremia,
nmAb levels.
Measurement of viral RNA load (qRT-PCR). Quantitative realtime PCR (qRT-
PCR) was used for the measurement of viral loads, based on a previously validated
assay29, 30. In brief, RNA was extracted from 140 to 1000 µl of frozen fluids,
depending on availability, using the QIAamp Viral RNA Mini Kit or QIAamp
Circulating Nucleic Acid kit (Qiagen, Hilden, Germany). The total nucleic acid was
eluted in two centrifugation steps with 40 µl of Buffer AVE each. A qRT-PCR
reaction was then carried out with 20 µl of samples and 10 µl of primer, probes, and
TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Foster City, CA). We
used pre-combined probe and primers (500 nM primers and 250 nM probe; IDT
Technologies, Coralville, IA). The primer and probe sequences were designed to
match the sequences of the Brazilian ZIKV isolate KU321639 and were as follows:
primer 1 5′TTGAAGAGGCTGCCAGC3′; primer 2 5′CCCACTGAACCCCATC-
TATTG3′; probe 5′TGAGACCCAGTGATGGCTTGATTGC3′. The probe was
double-quenched (ZEN/Iowa Black FQ) and labeled with the FAM dye (IDT
Technologies, Coralville, IA). Tenfold serial dilutions of a 401 bp in vitro RNA
transcript encoding the ZIKV capsid gene (KU321639) starting at approximately
5 × 105 RNA copies µl−1 were used as standards. Results were reported as the
median equivalent viral RNA genomes per ml. The limit of detection was between
12 and 90 viral RNA copies ml−1, depending on the extracted volumes. ZIKV-
positive and ZIKV-negative samples were included in every run. Viral load data
was analyzed with QuantStudio Real-Time PCR Software v1.3 and graphed using
GraphPad Prism 7.0a.
Zika virus genetic analysis. RNA was extracted from the samples by the same
methods as described in the qRT-PCR section. Deep sequencing was performed
using a PCR amplicon-based approach31, 32. Briefly, cDNA was reverse transcribed
from 5 μl of RNA using SuperScript IV (Invitrogen). ZIKV cDNA (2.5 μl per
reaction) was amplified in 35×400 bp fragments from two multiplexed PCR reac-
tions using Q5 DNA High-fidelity Polymerase (New England Biolabs). The
amplified ZIKV cDNA fragments (50 ng) were prepared for sequencing using the
Kapa Hyper prep kit (Kapa Biosystems) and SureSelect XT2 indexes (Agilent).
Agencourt AMPure XP beads (Beckman Coulter) were used for all purification
steps. Paired-end 251 nt reads were generated on the MiSeq using the V2 500 cycle
kit (Illumina).
Demultiplexing was performed by the Illumina instrument. The primer
sequences were removed from the reads and bases with Phred quality scores <20
were removed by Trimmomatic33. The reads were then aligned to the complete
genome of a ZIKV isolate from the Dominican Republic, 2016 (GenBank:
KU853012) using Novoalign v3.04.04 (www.novocraft.com). Samtools was used to
sort the aligned BAM files34. The consensus and intrahost variants >0.25 frequency
were called using Geneious v9.1.535 before generating consensus sequences. Calling
consensus nucleotides at each position required at least ×25 coverage and variant
calling required at least ×100 coverage. The consensus sequence for the input Zika
virus (Rio U-1/2016) was 100% identical to the previously published sequence
(GenBank KU926309). A conservative 0.25 frequency cut-off was used to (1) help
account for variations in input ZIKV concentrations and (2) to focus on mutations
that may be under strong selective pressures. The sequencing statistics are
presented in Supplementary Table 2 and the data are available in the NCBI
BioProject collection (PRJNA413046).
In vivo human antibody quantitation by ELISA. The presence of the recombinant
nmAbs in sera was quantitated with an ELISA specific for human Abs. In brief, 96-
well ELISA plates were coated overnight with 5 µg ml−1 of the monkey Ab-
adsorbed goat anti-human IgG (Southern Biotech, 2049-01) diluted in phosphate-
buffered saline (PBS). Each plate was washed with PBS-Tween20 and the wells were
blocked with 5% non-fat dry milk in PBS for 1 h at 37 °C. Subsequently, the plate
was washed with PBS and serum samples were added to designated wells. After 1 h
incubation at 37 °C, the plate was washed, and detection was carried out using a
HRP-conjugated goat anti-human IgG (Southern Biotech, 2045-05), which was
added to all wells at a dilution of 1:10,000. Following a 1 h incubation at 37 °C, the
plate was washed with PBS-Tween20 and developed with TMB substrate (Milli-
pore) at room temperature for 3–4 min. Reaction was then stopped with TMB stop
solution, and absorbance was read at 450 nm.
Data availability. The data sets generated during and/or analyzed during the
current study are available from the corresponding author on reasonable request.
The ZIKV sequencing data is available in the NCBI BioProject collection under
accession code PRJNA413046.
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